The HTA Core Model ® —10 Years of Developing an International Framework to Share Multidimensional Value Assessment

Kristensen, Finn Børlum; Lampe, Kristian; Wild, Claudia; Cerbo, Marina; Goettsch, Wim; Becla, Lidia

doi:10.1016/j.jval.2016.12.010

Cited by 72 publications

(69 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another solution to limited resources would be to adapt and adopt HTAs from other jurisdictions. For instance, the joint assessments resulting from the European collaboration in the field of relative effectiveness assessments are an example; contextualization of these assessments though remains the remit of the national entities (24).…”

Section: Potential Solutionsmentioning

confidence: 99%

Addressing the challenges of implementing a Health Technology Assessment Policy Framework in South Africa

Mueller

2020

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Objective South Africa's commitment to progressively achieve universal health coverage can lead to the effective and appropriate use of Health Technology Assessment (HTA) to strengthen the healthcare system. The study aimed to analyze the challenges faced in the formal implementation and utilization of HTA in the public health sector. Methods Review and analysis of health technology policies and legislation introduced in South Africa since 1965 serves as the backbone of this study. Walt and Gilson's health policy triangle framework and Kingdon's model were used for data analysis. In addition, a semi-structured survey was conducted among key stakeholders, including those attending HTA workshops that were held in 2016 and 2017. Results The document review identified appropriate legislative and policy framework for informing healthcare decisions. Survey participants (n = 55) reported limited political support, local capacity, and awareness of HTA as barriers to implementing HTA. They noted that adequate financial resources and availability and sharing of quality data are primary drivers for HTA development. Effective governance, collaboration, and cooperation between key stakeholders of the healthcare system were suggested as possible ways forward for the institutionalization of HTA. Conclusion The South African government's goal to introduce the national health insurance program provides an excellent opportunity to formally introduce the use of HTA in decision making. Individual capacity development supported by institutional and organizational environments is urgently needed to achieve its full potential.

show abstract

Section: Potential Solutionsmentioning

confidence: 99%

Addressing the challenges of implementing a Health Technology Assessment Policy Framework in South Africa

Mueller

2020

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

“…HTA procedures and decision-making elements differ per country. According to European network for health technology assessment's (EUnetHTA's) HTA Core Model ® , HTA elements can include (a) health problem and current use of technology, (b) description and technical characteristics, (c) safety, and (d) clinical effectiveness, and can further be expanded to include (e) costs and economic evaluation, (f) ethical analysis, (g) organizational aspects, (h) patient and social aspects, and (i) legal aspects [1].…”

Section: Introductionmentioning

confidence: 99%

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Overbeeke

Forrester

Simoens

et al. 2020

Patient

View full text Add to dashboard Cite

Objective Patient preferences can be informative for health technology assessment (HTA) and payer decision making. However, applications may be different per country. The aim of this study therefore was to investigate HTA representatives' opinions on whether and how to incorporate patient preferences in HTA in their respective countries. Methods Three country-specific focus groups were conducted with three to seven HTA representatives from Germany, Belgium, and Canada. A predefined focus group guide was used that covered topics relating to how patient preferences can be used in HTA, namely HTA stage, weight, impact, and quality, as well as a case example of gene therapy. Transcripts were analyzed using NVivo 12 following thematic analysis. Results Across all HTA bodies, an interest in the use of patient preferences was observed for scientific advice and value assessments, but not through incorporation in quality-adjusted life-years and multi-criteria decision analysis. HTA representatives found it difficult to determine the weight patient preferences may receive in decision making, but thought it could have an impact on payer decision making if the study is of acceptable quality. Conclusions In the near future it may be impossible to achieve structural integration of patient preferences with other evidence in HTA (e.g., in cost-effectiveness analysis), but HTA bodies are willing to incorporate patient preferences in other HTA sections as supportive evidence. To allow for that use, future work should focus on meeting HTA and payer needs when conducting patient preference studies and on education of HTA and payer representatives regarding these studies.

show abstract

“…The aim of the first session was to reflect on the benefits of the early dialogues (EDs) between stakeholders and to align evidence requirements for drug authorization and coverage that focus on CEE countries. In his introduction, Finn Børlum Kristensen (former head of EUnetHTA) highlighted that dialogs between national stakeholders started at the regulatory level and continued with HTA early scientific advice [5,6]. Maggie Galbraith (Haute Autorité de Santé, France) explained the four key benefits of ED: quality, consistency, timeliness, and efficiency and highlighted that an ED takes 4-4.5 months [7].…”

Section: Second Daymentioning

confidence: 99%

Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019

Inotai

Németh²

2019

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) organized its first Central Eastern European regional meeting in 2019 in Warsaw, Poland. Area covered: The scientific program of the two-day conference covered a broad range of topics presented from the perspective of the region. Specifically, the focus was on cross-country collaboration within different steps of health technology assessment (HTA) and the need for local HTA adaptations in decision-making. Expert commentary: Attended by approximately 200 delegates from many countries and by several high level ISPOR leaders, the conference provided a valuable opportunity to exchange knowledge and strengthen the scientific network among experts from different stakeholder groups on issues specific to the region. ARTICLE HISTORY

show abstract

The HTA Core Model ® —10 Years of Developing an International Framework to Share Multidimensional Value Assessment

Abstract: The HTA Core Model is now available for everyone around the world as a framework for assessing value.

Cited by 72 publications

References 12 publications

Addressing the challenges of implementing a Health Technology Assessment Policy Framework in South Africa

Addressing the challenges of implementing a Health Technology Assessment Policy Framework in South Africa

Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives

Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019

Contact Info

Product

Resources

About